Favorable benefit–risk ratio with teriflunomide treatment in relapsing-remitting multiple sclerosis: Results of the 2-year, multicenter, prospective, noninterventional TAURUS MS study in Austria

OBJECTIVES: A prospective, multicenter, open-label, noninterventional study assessed the efficacy, safety, tolerability, and patient satisfaction with teriflunomide therapy over a 24-month follow-up period under real-world conditions in Austria. METHODS: An all-comer population aged ≥18 years was fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Guger, Michael, Ackerl, Michael Matthias, Heine, Martin, Hofinger-Renner, Christiane, Spiss, Heinrich Karl, Taut, Andrea, Unger, Karin, Leutmezer, Fritz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919225/
https://www.ncbi.nlm.nih.gov/pubmed/35295745
http://dx.doi.org/10.1016/j.ensci.2022.100396

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919225/
https://www.ncbi.nlm.nih.gov/pubmed/35295745
http://dx.doi.org/10.1016/j.ensci.2022.100396

Ejemplares similares